ReviewMolecular diversity2020
Coumarins: antifungal effectiveness and future therapeutic scope.
Review in Molecular diversity, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 20 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
20 citing papers in PubMed, 85 citations in OpenAlex.
- Article
- A Coumarin- and Phthalide-Rich Fraction From Baichuan Baile Formula Alleviates Reserpine-Induced Depression-Like Behaviors by Modulating the Monoaminergic System and Gut Microbiota.Chemistry & biodiversity · 2026Article
- Thiazolyl-Methylthio-1,3,4-Thiadiazole Hybrids as Halicin Analogues with Antimicrobial and Antibiofilm Activities: Chemical Development, Biological Assessment, and 2D-QSAR Study.Antibiotics (Basel, Switzerland) · 2026Article
- 7-Prenyloxycoumarins as Promising Antileishmanial Agents: In Vitro, In Vivo, and In Silico Evaluation AgainstPharmaceuticals (Basel, Switzerland) · 2026Article
- The Role of Coumarins in Drug Discovery: Pharmacological Insights and Structural Innovations.Current topics in medicinal chemistry · 2026Review
- Recent Developments on Coumarin Hybrids as Antimicrobial Agents.Antibiotics (Basel, Switzerland) · 2025Review
- Pathogenic Ralstonia solanacearum in Agriculture: A Review of Prevention and Control Strategies Based on Natural Products.Current microbiology · 2025Review
- In sight on olive oil maceration and supercritical COScientific reports · 2024Article
- Topical Nanoemulsions as Delivery Systems for Green Extracts ofPharmaceutics · 2024Article
- Syntheses, reactivity, and biological applications of coumarins.Frontiers in chemistry · 2024Review
- Biological evaluation of novel amidino substituted coumarin-benzazole hybrids as promising therapeutic agents.RSC medicinal chemistry · 2023Article
- Bioactivity and toxicity of coumarins from African medicinal plants.Frontiers in pharmacology · 2023Review
- Antifungal Activity of 6-Methylcoumarin againstJournal of fungi (Basel, Switzerland) · 2022Article
- The liquid phase of 4,4'-trimethylenedipiperidine: a safe and greener dual-task agent for clean and facile synthesis of coumarin derivatives.Molecular diversity · 2022Article
- Arylcoumarin perturbs SARS-CoV-2 pathogenesis by targeting the S-protein/ACE2 interaction.Scientific reports · 2022Article
- Effective Synthesis and Biological Evaluation of Functionalized 2,3-Dihydrofuro[3,2-ACS omega · 2022Article
- Characterisation, pathogenicity and hydrolytic enzyme profiling of selected Fusarium species and their inhibition by novel coumarins.Archives of microbiology · 2021Article
- Chromenol Derivatives as Novel Antifungal Agents: Synthesis, In Silico and In Vitro Evaluation.Molecules (Basel, Switzerland) · 2021Article
- Evaluation of effectiveness aqueous extract for some leaves of wild edible plants in Egypt as anti-fungal and anti-toxigenic.Heliyon · 2021Article
- Asymmetric organocatalyzed synthesis of coumarin derivatives.Beilstein journal of organic chemistry · 2021Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The antifungals that are in current clinical practice have a high occurrence of a side effect and multidrug resistance (MDR). Researchers across the globe are trying to develop a suitable antifungal that has minimum side effect as well as no MDR issues. Due to serious undesired effects connected with individual antifungals, it is now necessary to introduce novel and effective drugs having numerous potentials to regulate complex therapeutic targets of several fungal infections simultaneously. Thus, by taking a lead from this subject, synthesis of potent antifungals from coumarin moiety could contribute to the development of promising antifungal. Its resemblance and structural diversity make it possible to produce an auspicious antifungal candidate. Due to the natural origin of coumarin, its presence in diversity, and their broad spectrum of pharmacological activities, it secures an important place for the researcher to investigate and develop it as a promising antifungal in future. This manuscript discusses the bioavailability of coumarin (natural secondary metabolic molecule) that has privileged scaffold for many mycologists to develop it as a broad-spectrum antifungal against several opportunistic mycoses. As a result, several different kinds of coumarin derivatives were synthesized and their antifungal properties were evaluated. This review compiles various coumarin derivatives broadly investigated for antifungal activities to understand its current status and future therapeutic scope in antifungal therapy.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.